151 – 160 of 365
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
What ails the beta-cell?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Degradation of GIP but not of GLP-1 is reduced after protein ingestion in obese subjects
2010) 46th Annual Meeting of the European-Association-for-the- Study-of-Diabetes (EASD) In Diabetologia 53(Suppl. 1). p.646-646(
- Contribution to journal › Published meeting abstract
-
Mark
CART is upregulated in islets of type 2 diabetic patients, stimulates insulin secretion, inhibits glucagon secretion and protects against beta cell death
2010) 46th Annual Meeting of the European-Association-for-the- Study-of-Diabetes (EASD) In Diabetologia 53(Suppl. 1). p.95-95(
- Contribution to journal › Published meeting abstract
-
Mark
Cocaine- and amphetamine-regulated transcript (CART) is upregulated in islets of type-2 diabetic patients to stimulate insulin secretion, inhibit glucagon secretion and protect against beta cell death
(
- Contribution to journal › Published meeting abstract
-
Mark
Overexpression of Foxf2 in adipose tissue is associated with lower levels of IRS1 and decreased glucose uptake in vivo
(
- Contribution to journal › Article
-
Mark
Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice.
(
- Contribution to journal › Article
-
Mark
Changes in cerebrospinal fluid insulin during non-neurological surgery
2010) 23rd Congress Meeting of European-College-of-Neuropsychopharmacology In European Neuropsychopharmacology 20. p.328-329(
- Contribution to journal › Published meeting abstract
-
Mark
The incretin effect is apparent after lipid challenge in healthy humans
2010) 46th Annual Meeting of the European-Association-for-the- Study-of-Diabetes (EASD) In Diabetologia 53(Suppl. 1). p.648-648(
- Contribution to journal › Published meeting abstract
-
Mark
Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy.
(
- Contribution to journal › Article
-
Mark
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
(
- Contribution to journal › Article